Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine

BIOLOGICAL4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Gastroenteritis Escherichia ColiImmunisation

Phase 1

Phase I Study of ETEC Vaccine

CompletedNCT01147445

National Institute of Allergy and Infectious Diseases (NIAID)Gastroenteritis Escherichia Coli

Start: 2010-09-13End: 2012-06-08Updated: 2025-10-07

Safety of Sublingual dmLT for ETEC

CompletedNCT02052934

National Institute of Allergy and Infectious Diseases (NIAID)Gastroenteritis Escherichia Coli

Start: 2014-03-10End: 2016-11-02Updated: 2019-01-28

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

CompletedNCT02531685

National Institute of Allergy and Infectious Diseases (NIAID)Gastroenteritis Escherichia Coli

Start: 2016-06-02End: 2020-05-04Updated: 2020-10-26

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

TerminatedNCT03548064

National Institute of Allergy and Infectious Diseases (NIAID)Gastroenteritis Escherichia Coli, Immunisation

Start: 2019-03-10End: 2020-12-31Updated: 2025-05-21

Related Papers

Safety and immunogenicity of a recombinant double-mutant heat-labile toxin derived from enterotoxigenic Escherichia coli in healthy Bangladeshi adults delivered by three different routes

Frontiers in Bacteriology2025-07-161 citations

Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermally.

2025-02-011 citations

Safety and Immunogenicity of a Single Oral Dose of Recombinant Double Mutant Heat-Labile Toxin Derived from Enterotoxigenic Escherichia coli

Clinical and Vaccine Immunology2013-09-1959 citations